Laboratoires FILLMED files for Health Canada Approval of ART-FILLER® Injectables in
Crescita and FILLMED entered into an agreement in
The ART-FILLER range of products were submitted for approval by
In 2018, the dermal filler market in
The Company is planning to launch FILLMED's NCTF products onto the Canadian market in the first half of 2021, while it anticipates launching the ART-FILLER range imminently following its approval by
"With the increasing popularity of minimally invasive and non-invasive aesthetic procedures and the increasing public acceptance of these procedures, we are excited to enter the growing medical aesthetic market with such remarkable, high quality products, which are already well-known and widely used in over 60 countries across the globe," said
"With Crescita, we have a partnership with a company that has strong commercial presence in
About
Crescita (TSX: CTX and OTC US: CRRTF) is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. The Company offers a portfolio of non-prescription skincare products and early to commercial stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin.
Supported by a sales force covering
Crescita's expertise in product formulation and development can be leveraged in combination with its patented transdermal delivery technologies to develop and manufacture creams, liquids, gels, ointments and serums under its CDMO infrastructure. The Company operates out of a 50,000 square-foot facility located in
About FILLMED
FILLMED has designed, developed and marketed anti-aging products for aesthetic medicine professionals since 1978: for surgeons, dermatologists and aesthetic medicine practitioners. These products correct the signs of aging and improve skin quality. Over the years, NCTF® and ART FILLER® injectables ranges have become benchmark products for both practitioners and patients. They are distributed extensively in more than 60 different countries across the globe.
About NCTF® 135 HA
FILLMED NCTF 135 HA is an injectable solution indicated for the rejuvenation of the skin, improvement of skin quality and fine lines. Since 1978, NCTF has been the undisputed leader in skin rejuvenation with over 3 million bottles sold in more than 60 countries in 2020. Comprising hyaluronic acid and revitalizing ingredients, NCTF 135 HA is a hydration booster providing the essential ingredients for skin health. It slows and corrects age-related skin changes: dryness, dullness, uneven complexion, dilated pores and wrinkles.
About ART-FILLER®
Developed, manufactured and launched in 2016 by Laboratoires FILLMED, the ART FILLER range benefits from an innovation in R&D: the Tri-Hyal® technology. Made of non-animal origin hyaluronic acid, the gels feature a perfect equilibrium between free hyaluronic acid, long chains and very long chains hyaluronic acid. For an optimal injection experience, each product contains 0.3% lidocaine.
The high performance and the tolerance of
Forward-Looking Statements
This press release contains "forward-looking information" as defined under Canadian securities laws (collectively, "forward-looking statements"). The words "plans", "expects", "does not expect", "goals", "seek", "strategy", "future", "estimates", "intends", "anticipates", "does not anticipate", "projected", "believes" or variations of such words and phrases or statements to the effect that certain actions, events or results "may", "will", "could", "would", "should", "might", "likely", "occur", "be achieved" "continue" or "temporary" and similar expressions identify forward-looking statements and include statements regarding the Company's plans, objectives and responses to the COVID-19 pandemic. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances contain forward-looking statements.
Forward-looking statements are not historical facts but instead represent management's expectations, estimates, projections and assumptions regarding future events or circumstances. Such forward-looking statements are qualified in their entirety by the inherent risks, uncertainties and changes in circumstances surrounding future expectations which are difficult to predict and many of which are beyond the control of the Company. Forward-looking statements are necessarily based on a number of estimates and assumptions that, while considered reasonable by management of the Company as of the date of this press release, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Material factors and assumptions used to develop the forward-looking statements, and material risk factors that could cause actual results to differ materially from the forward-looking statements, include but are not limited to the risks of, and future impacts related to, COVID-19, including the response of domestic and international governments to the virus; the impact of COVID-19 on the Company's operations, personnel, supply chain, product sales, royalties, customer demand and financial flexibility; changes in the business or affairs of Crescita; the ability of Crescita's licensees to successfully market its products; competitive factors in the industries in which Crescita operates; relationships with customers, suppliers and licensees; changes in legal and regulatory requirements; foreign exchange and interest rates; prevailing economic conditions; and other factors, many of which are beyond the control of Crescita.
Additional factors that could cause Crescita's actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the risk factors included in Crescita's most recent Annual Information Form under the heading "Risks Factors", and as described from time to time in the reports and disclosure documents filed by Crescita with Canadian securities regulatory authorities and commissions. These and other factors should be considered carefully, and readers should not place undue reliance on Crescita's forward-looking statements when making decisions, as forward-looking statements involve significant risks and uncertainties. Forward-looking statements should not be read as guarantees of future performance or results and will not necessarily be accurate indications of whether or not the times at or by which such performance or results will be achieved.
All forward-looking statements are based only on information currently available to the Company and are made as of the date of this press release. Except as expressly required by applicable Canadian securities law, the Company assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. All forward-looking statements in this press release are qualified by these cautionary statements.
1 Source: "Global Dermal Fillers Market to Hit |
View original content to download multimedia:http://www.prnewswire.com/news-releases/crescita-announces-filing-of-new-medical-device-license-301212507.html
SOURCE
© Canada Newswire, source